Abstract
The history of heparin is described from its initial discovery in 1916 to recent developments in knowledge of its mechanism of action and clinical use. Commercial production started soon after its discovery, in the 1920s, and improved purification methods led to animal studies and the first clinical trials in the 1930s. Research into heparin’s chemical structure proved difficult, with uncertainty about the uronic acid moiety and the N-acetyl content, but the structure of the basic disaccharide unit was established by the 1960s, though knowledge of the heterogeneity and fine structure of heparin chains continued to accumulate over the next 20 years. In 1976, it was found that only one third of heparin chains bound with high affinity to antithrombin, and subsequent studies identified a unique pentasaccharide sequence, which was essential for antithrombin binding and anticoagulant activity – this pentasaccharide was synthesised in 1983. Clinical usage of heparin continued to increase and two major developments were the use of low- dose heparin for prevention of deep vein thrombosis and pulmonary embolism, and the development of low-molecular-weight heparin as a separate drug.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abildgaard U (1968) Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 21(1):89–91
Abildgaard U (1975) Heparin cofactor and antithrombin. Thromb Diath Haemorrh 33(1):38–42
Adams SS, Smith KL (1950) The use of sulphated whole blood in the assay of heparin. J Pharm Pharmacol 2(11):836–846
Alban S (2011) Adverse effects of heparin. In: Lever R, Mulloy B, Page CP (eds) Heparin – a century of progress. Springer, Heidelberg 211–263
Anderson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC (1976) Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9:575–583
Andersson L-O, Barrowcliffe TW, Holmer E, Söderström G (1979) Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated Factor X. Effect of heparin neutralisation in plasma. Thromb Res 15:531–541
Anonymous (1975) Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 2(7924):45–51
Bangham DR, Woodward PM (1970) A collaborative study of heparins from different sources. Bull World Health Organ 42(1):129–149
Barritt D, Jordan S (1960) Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1:1309–1312
Barrowcliffe TW (1989) Heparin assays and standardisation. In: Lane DA, Lindahl U (eds) Heparin, chemical and biological properties, clinical applications. Edward Arnold, London
Barrowcliffe TW (1995) Low molecular weight heparin(s). Br J Haematol 90(1):1–7
Barrowcliffe TW, Gutteridge JMC, Dormandy TL (1975) The effect of fatty acid autoxidation products on blood coagulation. Thromb Diath Haemorrh 33:271–277
Barrowcliffe TW, Johnson EA, Eggleton CA, Thomas DP (1978) Anticoagulant activities of lung and mucosal heparins. Thromb Res 12:27–36
Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP (1985) Standardisation of low molecular weight heparins: a collaborative study. Thromb Haemost 54:675–679
Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP (1988) An International Standard for LMW heparin. Thromb Haemost 60:1–7
Best CH (1959) Preparation of heparin and its use in the first clinical cases. Circulation 19:79–86
Björk I, Olson ST, Shore JD (1989) Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting preteinases. In: Lane DA, Lindahl U (eds) Heparin, chemical and biological properties, clinical applications. Edward Arnold, London
Bratt G, Törnebohm E, Granqvist S, Aberg W, Lockner D (1985) A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 54(4):813–817
Brinkhous KM, Smith HP Jr, Warner ED, Seegers WH (1939) The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol 125:683–687
Carlström AS, Liedén K, Björk I (1977) Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 11(6):785–797
Carrell R, Skinner R, Warden M, Whisstock J (1995) Antithrombin and heparin. Mol Med Today 1(5):226–231
Charles AF, Scott DA (1933a) Studies on heparin I: the preparation of heparin. J Biol Chem 102:425–429
Charles AF, Scott DA (1933b) Studies on heparin II: heparin in various tissues. J Biol Chem 102:431–435
Charles AF, Todd AR (1940) Observations on the structure of the barium salt of heparin. Biochem J 34(1):112–118
Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116(2):492–499
Cifonelli JA, Dorfman A (1962) The uronic acid of heparin. Biochem Biophys Res Commun 7:41–45
Collins R, Scrimgeour A, Yusef S, Peto R (1988) Reductions in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urological surgery. N Engl J Med 318:1162–1173
Coyne E (1981) Heparin – past, present and future. In: Lundblad RL, Brown WV, Mann KG, Roberts HR (eds) Chemistry and biology of heparin. Elsevier, New York
Crafoord C (1939) Heparin and post-operative thrombosis. Acta Chir Scand 82:319–333
Damus PS, Hicks M, Rosenberg RD (1973) Anticoagulant action of heparin. Nature 246(5432):355–357
Danielsson A, Raub E, Lindahl U, Björk I (1986) Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 261(33):15467–15473
Denson KW, Bonnar J (1973) The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 30(3):471–479
Doyon M, Morel A, Policard A (1911) Estraition directe de l’antithrombine du foie. Influence de la congelation du sang. C R Soc Biol Paris 70:341–346
Foster RHK, Nutley NJ (1942) The assay of heparin. J Lab Clin Med 27:820–827
Gallus AS, Hirsh J, Tutle RJ, Trebilcock R, O'Brien SE, Carroll JJ, Minden JH, Hudecki SM (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 288(11):545–551
Gomperts ED, Zucker ML (1978) Heparin, brain thromboplastin and the insensitivity of the prothrombin time to heparin activity. Thromb Res 12(1):105–117
Gray E, Mulloy B, Barrowcliffe TW (2008) Heparin and low-molecular-weight heparin. Thromb Haemost 99:807–818
Gray E (2011) Standardisation of Unfractionated and Low-Molecular-Weight Heparin. In: Lever R, Mulloy B, Page CP (eds) Heparin – a century of progress. Springer, Heidelberg 65–76
Griffith MJ (1979) Kinetic analysis of the heparin-enhanced antithrombin III/thrombin reaction. Reaction rate enhancement by heparin-thrombin association. J Biol Chem 254(23):12044–12049
Höök M, Björk I, Hopwood J, Lindahl U (1976) Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 66(1):90–93
Howell WH (1925) The purification of heparin and its presence in blood. Am J Physiol 17:553–562
Howell WH (1928) The purification of heparin and its chemical and physiological reactions. Bull John Hopkins Hosp 42:199–206
Howell WH, Holt E (1918) Two new factors in blood coagulation – heparin and pro-antithrombin. Am J Physiol 47:328–341
Hull RD, Pineo GF (2000) Low-molecular-weight heparin in the treatment of venous thromboembolism. Semin Thromb Hemost 26(Suppl 1):61–67
Jaques LB (1940) The heparins of various mammalian species and their relative anti-coagulant potency. Science 92(2395):488–489
Jaques LB (1978) Addendum: the discovery of heparin. Semin Thromb Hemost 4:350–353
Jaques LB, Charles AF (1941) The assay of heparin. Quart J Pharm Pharmacol 14:1–15
Johnson EA (1992) Historical note. In: Barrowcliffe TW, Johnson EA, Thomas DP (eds) Low molecular weight heparin. Wiley, Chichester
Johnson EA, Mulloy B (1976) The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 51(1):119–127
Johnson EA, Kirkwood TB, Stirling Y, Perez-Requejo JL, Ingram GI, Bangham DR, Brozović M (1976) Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 35(3):586–591
Jorpes E (1935) The chemistry of heparin. Biochem J 29(8):1817–1830
Jorpes E, Bergström S (1936) Der aminozucker des heparins. Hoppe Seylers Z Physiol Chem 244:253–259
Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crellin RQ, Wessler S, Yin ET (1972) Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet 2(7768):101–106
Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J (1982) Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 284:375–379
Kjems H, Wagner H (1948) A new method for the assay of heparin. Acta Pharmacol 4:155–163
Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG (1986) Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemost 56:243–246
Kuizenga MH, Nelson JW, Cartland GF (1943) The bioassay of heparin preparations. Am J Physiol 139:612–616
Lam LH, Silbert JE, Rosenberg RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69(2):570–577
Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U (1984) Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 218(3):725–732
League of Nations (1943/1944) Memorandum on a provisional International Standard for heparin. Bull Health Organ League Nations 10:51
Lindahl U, Axelsson OJ (1971) Identification of iduronic acid as the major sulfated uronic acid of heparin. J Biol Chem 246(1):74–82
Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson LA, Linker A (1979) Proc Natl Acad Sci USA 76(7):3198–3202
Lindahl U, Bäckström G, Thunberg L, Leder IG (1980) Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 77(11):6551–6555
Longas MO, Ferguson WS, Finlay TH (1980) Studies on the interaction of heparin with thrombin, antithrombin, and other plasma proteins. Arch Biochem Biophys 200(2):505–602
Mason EC (1924) A note on the use of heparin in blood transfusion. J Lab Clin Med 10:203–206
McIntosh FC (1941) A method for estimating the potency of heparin preparations. Biochem J 35:770–775
McLean J (1916) The thromboplastic action of cephalin. Am J Physiol 41:250–257
McLean J (1959) The discovery of heparin. Circulation 19(1):75–78
Nicolaides AN, Dupont PA, Desai S, Lewis JD, Douglas JN, Dodsworth H, Fourides G, Luck RJ, Jamieson CW (1972) Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. Lancet 2(7783):890–893
Perlin AS, Mackie DM, Dietrich CP (1971) Evidence for a (1→4)-linked 4-O-(-L-idopyranosyluronic acid 2-sulfate)-(2-deoxy-2-sulfoamino-D-glucopyranosyl 6-sulfate) sequence in heparin. Long-range H-H coupling in 4-deoxy-hex-4-enopyranosides. Carbohydr Res 18(2):185–194
Quick AJ (1935) The prothrombin in haemophilia and in obstructive jaundice. J Biol Chem 109:Ixiii–Ixiv
Quick AJ (1938a) On the action of heparin and its relation to thromboplastin. Am J Physiol 115:317–333
Quick AJ (1938b) The normal antithrombin of the blood and its relation to heparin. Am J Physiol 123:712–719
Reinert M, Winterstein A (1939) Contribution to the study of heparin. Arch Int Pharmacodyn Ther 62:47–48
Roden L (1989) Highlights in the history of heparin. In: Lane DA, Lindahl U (eds) Heparin, chemical and biological properties, clinical applications. Edward Arnold, London
Schmitz A, Fischer A (1933) Uber die chemische natur des heparins. III. Einige untersuchungen zur constitution des heparins. Hoppe Seylers Z Physiol Chem 216:274–280
Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Scherer R, Schulte H, van de Loo J (1984) Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 62(8):349–353
Schutz F (1941) Biological standardisation of anticoagulants. Quart J Pharm Pharmacol 14:45–48
Sharnoff JG, Kass HH, Mistica BA (1962) A plan of heparinization of the surgical patient to prevent postoperative thromboembolism. Surg Gynecol Obstet 115:75–79
Thomas DP (1992) Experimental studies in animals. In: Barrowcliffe TW, Johnson EA, Thomas DP (eds) Low molecular weight heparin. Wiley, Chichester
Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW (1981) Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost 45(3):214–218
Thunberg L, Bäckström G, Lindahl U (1982) Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 100:393–410
WHO Expert Committee on Biological Standardisation (1947/1948) Bull World Health Organ 1:9
Wolfrom ML, Rice FAH (1946) The uronic acid component of heparin. J Am Med Assoc 68:532–537
Wolfrom ML, Wang PY, Honda S (1969) On the distribution of sulphate in heparin. Carbohydr Res 11:179–185
Yin ET, Wessler S, Butler JV (1973) Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 81(2):298–310
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Barrowcliffe, T.W. (2012). History of Heparin. In: Lever, R., Mulloy, B., Page, C. (eds) Heparin - A Century of Progress. Handbook of Experimental Pharmacology, vol 207. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-23056-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-23056-1_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-23055-4
Online ISBN: 978-3-642-23056-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)